Bariatric Dose-ranging Study With Dexmedetomidine

• Status: Withdrawn
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

After obtaining informed consent,80 morbidly obese ASA II-III patients undergoing laparoscopic bariatric surgery procedures would be randomly assigned to one of four study groups at UTSWMC at Dallas.Hemodynamic paarameters, recovery times, postoperative pain scores, the need for rescue analgesics and side effects will be recorded.The purpose of this study is to determine the optimal linfusion rate of dexmedetomidine for maintaining cardiovscular stability during general anesthesia.

• Phase: Phase 4

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

Subjects may be included in the study only if they meet all of the following criteria:

1. Age 18 to 70 years

2. Undergo laparoscopic bariatric surgery requiring general anesthesia

3. Be capable of giving informed consent

4. ASA physical status I-III ( Appendix 1)

Exclusion Criteria:

1. Subjects will be excluded from the study for any of the following reasons:

2. With history of hypertension and allergy to dexmedetomidine

3. Patients who have greater than first degree heart block.

4. Performing major intracavitary surgery procedures

5. Patients who are pregnant or breast-feeding

6. History of alcohol or drug abuse